Investors might want to bet on BioNTech SE Sponsored ADR (BNTX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

European equities traded in the US as American depositary receipts were trending modestly lower late Friday morning, down 0.23% to 1,399.64 on the S&P Europe Select ADR Index. Despite the decline, the ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Check the time stamp on this data. Updated AI-Generated Signals for Biontech Se (BNTX) available here: BNTX. Type a few ...

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $120.00. The company’s shares opened today at ...

Investors in BioNTech SE (Symbol: BNTX) saw new options begin trading this week, for the September 19th expiration. One of the key data points that goes into the price an option buyer is willing ...

Investors, analysts and the interested public are invited to join the event MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company ...